Last reviewed · How we verify
Copaxone-Teva
Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell activity in multiple sclerosis.
Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell activity in multiple sclerosis. Used for Relapsing-remitting multiple sclerosis (RRMS), Clinically isolated syndrome (CIS) with high risk of MS.
At a glance
| Generic name | Copaxone-Teva |
|---|---|
| Also known as | glatiramer acetate |
| Sponsor | Biocad |
| Drug class | Immunomodulator; synthetic polypeptide |
| Target | T cell receptor (indirect); myelin basic protein mimic |
| Modality | Small molecule |
| Therapeutic area | Neurology; Immunology |
| Phase | Phase 3 |
Mechanism of action
Glatiramer acetate mimics myelin basic protein and acts as a decoy antigen, shifting the immune response from pro-inflammatory Th1 cells toward anti-inflammatory Th2 and regulatory T cells. This reduces attack on myelin-producing oligodendrocytes in the central nervous system. The mechanism also involves bystander suppression, where activated regulatory cells reduce inflammation more broadly.
Approved indications
- Relapsing-remitting multiple sclerosis (RRMS)
- Clinically isolated syndrome (CIS) with high risk of MS
Common side effects
- Injection site reactions (erythema, induration, pain)
- Lipoatrophy at injection sites
- Systemic post-injection reaction (flushing, chest tightness, dyspnea)
- Headache
- Flu-like symptoms
Key clinical trials
- Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis (PHASE3)
- Efficacy and Safety of GTR in Comparison to Copaxone® (PHASE3)
- An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Copaxone-Teva CI brief — competitive landscape report
- Copaxone-Teva updates RSS · CI watch RSS
- Biocad portfolio CI